(MedPage Today) — LOS ANGELES — In the PRESTIGE-AF trial, survivors of intracerebral hemorrhage (ICH) had good protection against future ischemic events using direct oral anticoagulants (DOACs) — though, as feared, bleeding side effects…
Source link : https://www.medpagetoday.com/meetingcoverage/isc/114144
Author :
Publish date : 2025-02-09 13:44:54
Copyright for syndicated content belongs to the linked Source.
